Select Page

The management team are pleased to announce the incorporation of Adoram Therapeutics SA in the Canton of Geneva in Switzerland. The co-founding team created the biotech company as a Spin-Off from the University of Geneva in order to pursue their passion in addressing unmet medical needs such as invasive cancers and immune-based disorders. CEO David Pejoski, CSO Hesham Hamed, and principal Advisor Leonardo Scapozza have all been based at the UNIGE Medical Research Center (CMU) adjacent to the Cantonal Hospitals (HUG) for several years, and are happy to collaborate in this joint venture in developing best-in-class small molecule therapies.